Thursday, 11 August 2022

Alcon launches intraocular lens AcrySof IQ Vivity in India

16 October 2021 | News

AcrySof IQ Vivity is the first and only presbyopia-correcting lens implant with proprietary wavefront-shaping technology for cataract surgery

Image Credit: Shutterstock

Image Credit: Shutterstock



Bengaluru-headquartered Alcon, a leader in eye care dedicated to helping people see brilliantly, announced the commercial launch of the first and only presbyopia-correcting intraocular lens (PC-IOL) with wavefront-shaping technology – the AcrySof IQ Vivity IOL (Vivity). The new PC-IOL is now available to Indian ophthalmologists for their patients undergoing cataract surgery. Cataracts usually impact older adults and are often linked to presbyopia, which reduces the ability to view near objects and is the most common refractive disorder in patients undergoing cataract surgery.


Vivity is the first and only extended depth of focus lens with Alcon’s proprietary X-WAVE technology, which stretches and shifts light without splitting it. Vivity delivers a continuous range of vision at various distances like monofocal-quality distance (far) with excellent intermediate (at arm’s length, e.g., reading the newspaper, working on a laptop) and functional near (up close, e.g., reading books, mobile phone), with a clinically proven exceptionally low rate of visual disturbances.  


Commemorating World Sight Day on October 14, Vivity aims to meet the needs of cataract patients interested in enhanced visual performance, reduced spectacle dependence while enabling for more independence.


Vivity expands Alcon’s growing portfolio of PC-IOLs and is built on Alcon’s trusted and proven AcrySof IQ IOL platform with implants exceeding 125 million eyes globally. According to results from two large independent clinical trials, patients who had the Vivity lens implanted experienced renewed vision and lifestyle benefits. Vivity patients reported 20/20 vision at a distance, more than 20/25 at intermediate and 20/32 for near vision.



× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account